vs

Side-by-side financial comparison of ALEXANDERS INC (ALX) and MEDIFAST INC (MED). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $53.3M, roughly 1.4× ALEXANDERS INC). On growth, ALEXANDERS INC posted the faster year-over-year revenue change (-4.7% vs -36.9%). Over the past eight quarters, ALEXANDERS INC's revenue compounded faster (-6.9% CAGR vs -34.4%).

Alexander's, Inc. is a real estate investment trust that owns 7 properties in New York metropolitan area, including 731 Lexington Avenue, the headquarters of Bloomberg L.P. It is controlled by Vornado Realty Trust. It was founded by George Farkas and Louis Schwadron in 1928.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

ALX vs MED — Head-to-Head

Bigger by revenue
MED
MED
1.4× larger
MED
$75.1M
$53.3M
ALX
Growing faster (revenue YoY)
ALX
ALX
+32.1% gap
ALX
-4.7%
-36.9%
MED
Faster 2-yr revenue CAGR
ALX
ALX
Annualised
ALX
-6.9%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALX
ALX
MED
MED
Revenue
$53.3M
$75.1M
Net Profit
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
Revenue YoY
-4.7%
-36.9%
Net Profit YoY
EPS (diluted)
$0.75
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALX
ALX
MED
MED
Q4 25
$53.3M
$75.1M
Q3 25
$53.4M
$89.4M
Q2 25
$51.6M
$105.6M
Q1 25
$54.9M
$115.7M
Q4 24
$55.9M
$119.0M
Q3 24
$55.7M
$140.2M
Q2 24
$53.4M
$168.6M
Q1 24
$61.4M
$174.7M
Net Profit
ALX
ALX
MED
MED
Q4 25
Q3 25
$6.0M
$-2.3M
Q2 25
$6.1M
$2.5M
Q1 25
$12.3M
$-772.0K
Q4 24
Q3 24
$6.7M
$1.1M
Q2 24
$8.4M
$-8.2M
Q1 24
$16.1M
$8.3M
Gross Margin
ALX
ALX
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
ALX
ALX
MED
MED
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
Q1 24
4.5%
Net Margin
ALX
ALX
MED
MED
Q4 25
Q3 25
11.2%
-2.5%
Q2 25
11.9%
2.3%
Q1 25
22.4%
-0.7%
Q4 24
Q3 24
12.0%
0.8%
Q2 24
15.7%
-4.8%
Q1 24
26.2%
4.8%
EPS (diluted)
ALX
ALX
MED
MED
Q4 25
$0.75
$-1.64
Q3 25
$1.16
$-0.21
Q2 25
$1.19
$0.22
Q1 25
$2.40
$-0.07
Q4 24
$2.39
$0.08
Q3 24
$1.30
$0.10
Q2 24
$1.63
$-0.75
Q1 24
$3.14
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALX
ALX
MED
MED
Cash + ST InvestmentsLiquidity on hand
$128.2M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$109.2M
$198.9M
Total Assets
$1.1B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALX
ALX
MED
MED
Q4 25
$128.2M
$167.3M
Q3 25
$286.1M
$173.5M
Q2 25
$313.0M
$162.7M
Q1 25
$319.9M
$164.6M
Q4 24
$338.5M
$162.3M
Q3 24
$354.8M
$170.0M
Q2 24
$410.9M
$163.5M
Q1 24
$526.3M
$156.4M
Stockholders' Equity
ALX
ALX
MED
MED
Q4 25
$109.2M
$198.9M
Q3 25
$128.3M
$214.7M
Q2 25
$145.4M
$216.0M
Q1 25
$163.1M
$211.0M
Q4 24
$176.9M
$210.1M
Q3 24
$190.7M
$207.3M
Q2 24
$212.5M
$205.3M
Q1 24
$230.1M
$211.0M
Total Assets
ALX
ALX
MED
MED
Q4 25
$1.1B
$248.0M
Q3 25
$1.3B
$268.2M
Q2 25
$1.3B
$269.3M
Q1 25
$1.3B
$280.0M
Q4 24
$1.3B
$284.2M
Q3 24
$1.4B
$291.2M
Q2 24
$1.5B
$293.5M
Q1 24
$1.4B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALX
ALX
MED
MED
Operating Cash FlowLast quarter
$73.4M
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALX
ALX
MED
MED
Q4 25
$73.4M
$-5.3M
Q3 25
$-9.3M
$12.1M
Q2 25
$43.6M
$-3.4M
Q1 25
$15.7M
$3.4M
Q4 24
$54.1M
$-4.9M
Q3 24
$-5.0M
$9.1M
Q2 24
$11.5M
$13.1M
Q1 24
$16.8M
$7.3M
Free Cash Flow
ALX
ALX
MED
MED
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
Q3 24
$7.7M
Q2 24
$11.1M
Q1 24
$5.4M
FCF Margin
ALX
ALX
MED
MED
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
Q3 24
5.5%
Q2 24
6.6%
Q1 24
3.1%
Capex Intensity
ALX
ALX
MED
MED
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
Q3 24
1.0%
Q2 24
1.1%
Q1 24
1.1%
Cash Conversion
ALX
ALX
MED
MED
Q4 25
Q3 25
-1.55×
Q2 25
7.12×
-1.36×
Q1 25
1.28×
Q4 24
Q3 24
-0.75×
8.04×
Q2 24
1.37×
Q1 24
1.04×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons